Clinical trial
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable…
NCT00112840 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00112840 |
|---|---|
| Title | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| Official title | A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | CCI-779, Bevacizumab |
| Enrollment | 60 |
| Start date | May 1, 2005 |
| Primary completion | Aug 9, 2010 |
| Completion | Sep 10, 2015 |
| First posted | Jun 3, 2005 |
| Last update posted | Feb 1, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: